EGFR-Mutated Lung Cancer Video Perspectives
Erminia Massarelli, MD, PhD, MS
Massarelli reports receiving honoraria from AstraZeneca and Merck; consulting and/or advising Bristol Myers Squibb Foundation, Genentech/Roche, Janssen Scientific Affairs, Merck, and Sanofi; serving on a speakers' bureau for AstraZeneca; receiving research funding from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Pfizer, and Tessa Therapeutics; and receiving travel, accommodations, and expenses from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, and Pfizer.
VIDEO: Disparities in care, management of EGFR-mutated lung cancer
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
The most important disparity that we could find out is that, actually, in the detection of the EGFR mutations, because if you look at the rates of molecular tests, you might see a disparity in, I would say, especially in the lower socio-economic areas.
Unfortunately, there are some insurance plans that are not allowing patients with lung cancer to have a comprehensive molecular test. They might actually limit it to just the EGFR molecular test. But that's not really the only one, because even if, let's say, if you have an EGFR, we talked about the exon 20. So, if you're not gonna detect, if there is just an EGFR detection, but then they don't specify that it's an EGFR exon 20 insertion, then the treatment is different, because these patients are not gonna respond to the Osimertinib (Tagrisso; AstraZeneca).
So, I would say the disparity is mainly in the detection of the EGFR sensitizing mutation, or exon 20 insertion.
